Evidence map›Paper›PMID 37172724›Full record

ArticleThe Journal of biological chemistry2023

Oculocerebrorenal syndrome of Lowe (OCRL) controls leukemic T-cell survival by preventing excessive PI(4,5)P

Huanzhao Chen, Chen Lu, Yuhui Tan, Marion Weber-Boyvat, Jie Zheng, Mengyang Xu, Jie Xiao, Shuang Liu, Zhiquan Tang, Chaofeng Lai and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 3 countries.

Huanzhao ChenMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Chen LuMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Yuhui TanMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Marion Weber-BoyvatMinerva Foundation Institute for Medical Research, Biomedicum 2U, Helsinki, Finland; Department of Anatomy, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Neurophysiology, Berlin, Germany.
Jie ZhengMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Mengyang XuMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Jie XiaoMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Shuang LiuMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Zhiquan TangMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Chaofeng LaiMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China.
Mingchuan LiMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China; Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Vesa M OlkkonenMinerva Foundation Institute for Medical Research, Biomedicum 2U, Helsinki, Finland; Department of Anatomy, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Daoguang YanMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China; Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China. Electronic address: tydg@jnu.edu.cn.
Wenbin ZhongMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, China; Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China. Electronic address: winbeyz@163.com.
Jinan University · CNUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is one of the deadliest and most aggressive hematological malignancies, but its pathological mechanism in controlling cell survival is not fully understood. Oculocerebrorenal syndrome of Lowe is a rare X-linked recessive disorder characterized by cataracts, intellectual disability, and proteinuria. This disease has been shown to be caused by mutation of oculocerebrorenal syndrome of Lowe 1 (OCRL1; OCRL), encoding a phosphatidylinositol 4,5-bisphosphate [PI(4,5)P

Indexed as

Cell MembranePhosphatidylinositol 4,5-DiphosphatePhosphoric Monoester HydrolasesPrecursor T-Cell Lymphoblastic Leukemia-LymphomaT-LymphocytesCalcium SignalingCell SurvivalCytosolGolgi ApparatusHumansHydrolysisLigandsMitochondriaOculocerebrorenal SyndromePhospholipase C betaProtein TransportLigandsOCRL protein, humanPhosphatidylinositol 4,5-DiphosphatePhospholipase C betaPhosphoric Monoester HydrolasesPLCB3 protein, humanCa(2+) homeostasisoculocerebrorenal syndrome of Lowe 1OSBP-related protein 4Lphosphatidylinositol 4,5-bisphosphateT-cell acute lymphoblastic leukemia

Identifiers

PMID37172724
PMCPMC10279916
OpenAlexW4376139558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.